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report
Abstract
A 43-year-old man was admitted to Surgery Department because 
of abdominal pain, vomiting, weight loss and flushes. Computed 
tomography (CT) examination revealed upper and middle abdo-
men tumor of about 110 × 110 mm. Histopathological analysis of 
the tissues obtained during the exploratory laparotomy confirmed 
WDNT (well-differentiated neuroendocrine tumor according to 
the WHO classification 2000). The patient received 5 doses of 
chemotherapy without any response. A positive result of 99mTc- 
[EDDA/Hynic] Octreotate scintigraphy (SRS) gave the possibility 
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of PRRT (peptide receptor radionuclide therapy). The patient 
was treated with the total dose of 400 mCi of 90Y-DOTA-TATE. 
CT performed after the PRRT revealed regression of the tumor 
size to 72 × 94 mm. A decrease of CgA level and release of 
symptoms were also observed. Aiming at the removal of the 
considerable diminished tumor the patient was qualified for the 
second laparotomy. “Cytoreduction” surgery with partial excision 
of the tumor was performed. Additionally tumor-affected appendix 
was removed. The second focus of WDNT (according to the WHO 
classification 2000) with Ki67 < 1% was found in the appendix. Pa-
thologists confirmed the above-mentioned lesions as independent 
(an extremely rare clinical situation). The following treatment with 
long-acting somatostatin analogs and 300 mCi of 90Y-DOTA-TATE 
resulted in further regression of the tumor size to 25 × 35 mm. 
Consecutive laparotomy is considered. If complete tumor removal 
might be achieved is an open question. The above case report 
shows the efficacy of combined therapy with the use of “hot” and 
“cold” somatostatin analogs not only in controlling the symp-
toms of the disease but also in obtaining tumor size regression 
making surgical intervention possible. Such a neoadjuvant therapy 
seems to be a promising tool in the management of patients with 
initially inoperable neuroendocrine tumors. 
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Introduction
Midgut tumors are the most common neuroendocrine tu-
mors (NET). Using morphological, immunohistochemical and bio-
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logical criteria, the classification distinguishes between well differ-
entiated neuroendocrine tumors (WDNT) with benign or uncertain 
behavior, well differentiated (low grade malignant) carcinomas and 
poorly differentiated (high grade malignant) carcinomas [1]. In 
15% of cases the coexistence with other neoplasms is observed. 
Surgery remains the gold standard in the management of NETs. 
Majority of the tumors are well differentiated, but even when 
small (less than 1 cm) have the potency to metastasize. The 
problem are the invasive unresectable tumors and those which 
are already metastasized at the time of diagnosis. WDNT usually 
express somatostatin receptors and they can be targeted with 
peptide receptor radionuclide therapy (PRRT). In patients with 
advanced neuroendocrine tumors PRRT might be not only the 
palliative but also neoadjuvant therapy [1, 2]. 
Case report 
43-years old man was admitted to Surgery Department be-
cause of abdominal pain, vomiting, weight loss and flushes. The 
computed tomography (CT) revealed the tumor of the upper and 
middle abdomen of about 110 × 110 mm. The initial cytological 
diagnosis was: tumor epigastrii probabiliter GIST (gastrointestinal 
stromal tumor). Immunohistochemical analysis changed the 
diagnosis to: carcinoma neuroendocrinale bene differentiatium; 
atypical carcinoid; emboliae neoplasmaticae vasorum lymphati-
corum. On 13th July 2005 patient underwent the exploratory lapa-
rotomy. The 150 over 200 mm tumor of the mesentery radix mobile 
towards aorta was found. The tumor was passing through the 
transverse mesocolon to the omental sac and through the lesser 
omentum was reaching liver. The tumor was separated from the 
small and large intestine, but the vessels of intestines and the celiac 
trunk bifurcation were involved and this made the lesion unresect-
able. There were no liver metastases found. The histopathological 
analysis of the tissues obtained during the surgery confirmed the 
diagnosis of well differentiated neuroendocrine tumor (WDNT 
according to the WHO classification 2000). From 29.08.2005 to 
06.01.2006 patient received 5 doses of chemotherapy streptozocin 
and 5-fluorouracil (5-FU) without any response. Patient was than 
referred to the Department of Endocrinology. Somatostatin 
receptor scintigraphy (SRS) with the use of 99m [EDDA/Hynic] 
Octreotate revealed pathological uptake in the upper and middle 
abdomen. This gave the possibility of peptide receptor radionu-
clide therapy (PRRT). Patient was treated with the total dose of 
400 mCi of 90Y-DOTA-TATE — 100 mCi per one cycle every 6–9 
weeks (from May to September 2006). To prevent nephrotoxicity 
an amino acid infusion lasting 8 to 10 hours was used during 
each cycle. The levels of 5-hydroxyindoleacetic acid (5-HIAA) 
and chromogranin A (CgA) prior to therapy were 21 mmol/24 h 
(normal range 10–40 mmol/24h) and 206.8 IU/l (normal range till 
18 IU/ml), respectively. The blood profile and routine laboratory 
parameters (electrolytes, liver function tests, creatinine, and urea) 
were checked prior to therapy, then after 7 and 14 days after 
the PRRT and then every month. The computed tomography 
performed after the radioisotope therapy (10.2006) showed re-
gression of the tumor size — from 110 × 110 mm at the time of 
diagnosis to 72 × 94 mm. The density of the tumor was 26 Houn-
sfield Units (HU). There was also the decrease in chromogranin 
A level to 47.1 IU/l and release of symptoms observed. After PRRT 
Figure 1. The picture presents the results of SRS (A) before the treatment (2005) after PRRT (2006) and after surgery (2009) with corresponding CT 
scans (B). Bellow the pictures the CgA levels are showed during the course of the treatment
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patient was treated for four months with long-acting somatostatin 
analogs. The following CT (03.2007) revealed further regression 
of the tumor size to 49 × 77 mm, with the tumor density 20–33 
HU. Aiming at the removal of the considerable diminished tumor 
the patient was qualified for the second laparotomy. “Cytoreduc-
tion” surgery with partial excision of the tumor was performed. On 
histopathological examination the diagnosis of well-differentiated 
neuroendocrine cancer with Ki67 3% was confirmed. Additionally 
the changed appendix was also excised. The second focus of 
WDNT (according to the WHO classification 2000) with Ki67 < 1% 
was found in the appendix. The pathologist confirmed above-men-
tioned lesions as independent. The tumor size on CT performed 
three months after surgery was 45 × 52 mm. Due to the very 
good response to the previous radionuclide therapy two additional 
doses of 90Y-DOTA-TATE (2 × 100 mCi) were applied in 2008, and 
the treatment with long acting somatostatin analog was continued. 
The CT performed one month after the PRRT revealed 26 × 36 mm 
remaining part of the tumor in the pancreatic body. 
Patient was referred again to the Surgery Department but the 
localization of the tumor (close to the vessels with a high risk of 
venous confluence and mesenteric vein injury) made the tumor inop-
erable and continuation of the radioisotope therapy was advocated. 
Eleven months after the last dose of radioisotope therapy patient 
received 100 mCi of 90Y-DOTA-TATE. After this therapy the tumor 
size was 25 × 35 mm. There was no hematotoxicity or nephrotoxic-
ity observed during and after the first and then repeated cycles of 
radioisotope therapy. The consecutive laparotomy is considered. If 
the complete tumor removal might be achieved is an open question. 
Discussion
Above case report shows the efficacy of combined therapy 
with use of “hot” and “cold” somatostatin analogs not only in 
controlling the symptoms of the disease but also in regression 
of the tumor size what enabled the surgical intervention. PRRT 
is usually used as a palliative treatment. Presented case report 
and other reported in literature show the efficacy of PRRT also 
as neoadjuvant therapy in the treatment of inoperable neuro-
endocrine tumors with positive somatostatin analogs receptor 
scintigraphy (SRS) [1]. SRS has proven its role in the diagnosis, 
staging of patients with gastroenteropancreatic neuroendocrine 
tumors (GEP-NET) and follow-up of patients with known disease. 
It might be also used for the selection of patients with inoperable 
or metastatic tumors for PRRT [2]. Because reported patient 
was treated with both — radionuclide therapy and long-acting 
somatostatin analogs — it is impossible to distinguish which 
therapy resulted in regression of tumor size. PRRT as guided 
therapy is probably mainly responsible for the regression of the 
tumor size. But as the results of a placebo-controlled, double-blind, 
phase IIIB study in patients with well-differentiated metastatic 
midgut NETs (PROMID) show the long-acting somatostatin ana-
logs are effective not only in symptoms control, but also might 
significantly lengthen time to tumor progression in patients with 
functionally active and inactive metastatic midgut NETs [2, 3]. The 
most favorable effect was observed in patients with low hepatic 
tumor load and resected primary tumor [3]. Moreover PROMID 
study have confirmed the antiproliferative effect of octreotide LAR 
in patients with well-differentiated metastatic GEP-NETs [3, 4]. 
Neoadjuvant therapy with both radiolabeled somatostatin 
analogs and “cold” somatostatin analogs seems to be a promis-
ing tool in the management of patients with initially inoperable 
neuroendocrine tumors [1–6].
Above case-report is also an example of the coexistence of 
two independent neuroendocrine tumors — well-differentiated 
neuroendocrine cancer of the mesentery radix with Ki67 3% and 
well-differentiated neuroendocrine tumor of the appendix with 
Ki67 < 1%. According to the literature up to 29% of patients with 
carcinoid tumor of the small intestine have multiple synchro-
nous carcinoid tumors [7]. The co-incidence of GEP-NET in differ-
ent organs is an extremely rare clinical situation. Only a few such 
tumors have been described so far [8–10]. The coexistence of 
GEP-NET and secondary primary malignancy (SPM) was observed 
in 2.3% of surgical cases and 8.1% of autopsy examinations [7]. 
In 59–87% GEP-NET and SPM were synchronous [11]. Meta-
chronous neoplasms were revealed 1–7 years after diagnosis of 
GEP-NET [11].
Conclusions
The presented case report shows the efficacy of combined 
therapy with the use of “hot” and “cold” somatostatin analogs not 
only in controlling the symptoms of the disease but also in obtain-
ing tumor size regression making surgical intervention possible.
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